Younger Than 55 Years Old and BRAF V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm

References

• Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Kurczyk A, Gawin M. Classification of thyroid tumors based on mass spectrometry imaging of tissue microarrays; a single-pixel approach. Int J Mol Sci. 2020;21(17):6289. doi:10.3390/ijms21176289
   PubMed Web of Science ®Google Scholar
• Miranda-Filho A, Lortet-Tieulent J, Bray F, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9(4):225–234. doi:10.1016/S2213-8587(21)00027-9
   PubMed Web of Science ®Google Scholar
• Guo L, Ma YQ, Yao Y. Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma. Sci Rep. 2019;9(1):75. doi:10.1038/s41598-018-36171-z
   PubMedGoogle Scholar
• Wang W, Su X, He K, et al. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: an updated study with more than 2000 consecutive patients. Cancer. 2016;122(2):198–206. doi:10.1002/cncr.29689
   PubMed Web of Science ®Google Scholar
• Dadafarin S, Carnazza M, Islam HK, Moscatello A, Tiwari RK, Geliebter J. Noncoding RNAs in papillary thyroid cancer: interaction with cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) and regulators of differentiation and lymph node metastasis. Adv Exp Med Biol. 2021;1350:145–155. doi:10.1007/978-3-030-83282-7_7
   PubMed Web of Science ®Google Scholar
• Pu W, Shi X, Yu P, Zhang M, Liu Z. Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat Commun. 2021;12(1):6058. doi:10.1038/s41467-021-26343-3
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang Y, Zhao J, et al. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR. Pathol Res Pract. 2019;215(4):761–765. doi:10.1016/j.prp.2019.01.006
   PubMed Web of Science ®Google Scholar
• Shafique K, LiVolsi VA, Montone K, Baloch ZW. Papillary thyroid microcarcinoma: reclassification to non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a retrospective clinicopathologic study. Endocr Pathol. 2018;29(4):339–345. doi:10.1007/s12022-018-9546-3
   PubMed Web of Science ®Google Scholar
• Sugitani I, Ito Y, Takeuchi D, et al. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the japan association of endocrine surgery task force on management for papillary thyroid microcarcinoma. Thyroid. 2021;31(2):183–192. doi:10.1089/thy.2020.0330
   PubMed Web of Science ®Google Scholar
• Albert-Gascó H, Ros-Bernal F. MAP/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. Int J Mol Sci. 2020;21(12):4471. doi:10.3390/ijms21124471
   PubMed Web of Science ®Google Scholar
• Asl ER, Amini M, Najafi S, et al. Interplay between MAPK/ERK signaling pathway and MicroRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci. 2021;278:119499. doi:10.1016/j.lfs.2021.119499
   PubMed Web of Science ®Google Scholar
• Dain Md Opo FA, Alsaiari AA, Rahman Molla MH, et al. Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process. Front Chem. 2022;10:986376. doi:10.3389/fchem.2022.986376
   PubMed Web of Science ®Google Scholar
• Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2022;34(1):9–18. doi:10.1097/CCO.0000000000000797
   PubMed Web of Science ®Google Scholar
• Cuomo F, Giani C, Cobellis G. The role of the kinase inhibitors in thyroid cancers. Pharmaceutics. 2022;14(5):1040. doi:10.3390/pharmaceutics14051040
   PubMed Web of Science ®Google Scholar
• Almubarak H, Qassem E, Alghofaili L, Alzahrani AS, Karakas B. Non-invasive molecular detection of minimal residual disease in papillary thyroid cancer patients. Front Oncol. 2019;9:1510. doi:10.3389/fonc.2019.01510
   PubMed Web of Science ®Google Scholar
• Silver JA, Bogatchenko M, Pusztaszeri M, et al. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm. J Otolaryngol Head Neck Surg. 2021;50(1):63. doi:10.1186/s40463-021-00543-9
   PubMed Web of Science ®Google Scholar
• Chen D, Qi W, Zhang P, et al. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma. Pathol Res Pract. 2018;214(2):303–307. doi:10.1016/j.prp.2017.09.001
   PubMed Web of Science ®Google Scholar
• Lee SE, Hwang TS, Choi YL, et al. Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAF(V600E) mutation. Thyroid. 2017;27(6):802–810. doi:10.1089/thy.2016.0547
   PubMed Web of Science ®Google Scholar
• Kim JK, Seong CY, Bae IE, et al. Comparison of immunohistochemistry and direct sequencing methods for identification of the BRAF(V600E) mutation in papillary thyroid carcinoma. Ann Surg Oncol. 2018;25(6):1775–1781. doi:10.1245/s10434-018-6460-3
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim JK, Kim GJ, Kang SW. TERT promoter and BRAF V600E mutations in papillary thyroid cancer: a single-institution experience in Korea. Cancers. 2022;14(19):4928. doi:10.3390/cancers14194928
   PubMed Web of Science ®Google Scholar
• Navarro-Locsin CG, Chang AM, Daroy ML, Alfon AC, Andal JJ, Padua PF. Clinical and histopathological profile of BRAF V600E mutation in conventional papillary thyroid carcinoma in a Filipino population. Malays J Pathol. 2016;38(2):141–148. PMID: 27568671.
   PubMed Web of Science ®Google Scholar
• Kure S, Ishino K. Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience. J Int Med Res. 2019;47(11):5560–5572. doi:10.1177/0300060519873481
   PubMed Web of Science ®Google Scholar
• Wu Y, Xu T, Cao X, et al. BRAF (V600E) vs. TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules. Cancer Biol Med. 2019;16(1):131–138. doi:10.20892/j.issn.2095-3941.2018.0291
   PubMed Web of Science ®Google Scholar
• Liu Z, Lv T, Xie C, Di Z. BRAF V600E gene mutation is associated with bilateral malignancy of papillary thyroid cancer. Am J Med Sci. 2018;356(2):130–134. doi:10.1016/j.amjms.2018.04.012
   PubMed Web of Science ®Google Scholar
• Celik M, Bulbul BY, Ayturk S, et al. The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer. Med Glas. 2020;17(1):30–34. doi:10.17392/1086-20
   Google Scholar
• Chakraborty D, Shakya S, Ballal S, Agarwal S, Bal C. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation. J Pediatr Endocrinol Metab. 2020;33(11):1465–1474. doi:10.1515/jpem-2020-0174
   PubMed Web of Science ®Google Scholar
• Gao J, Ma XP, Deng FS, Jiang L, Jia WD, Li M. Associations of the BRAF V600E mutation and PAQR3 protein expression with papillary thyroid carcinoma clinicopathological features. Pathol Oncol Res. 2020;26(3):1833–1841. doi:10.1007/s12253-019-00779-x
   PubMed Web of Science ®Google Scholar
• Sahin S, Daglar G. The effect of BRAF (V600E) mutation on lymph node involvement in papillary thyroid cancer. Turk J Surg. 2020;36(3):249–255. doi:10.47717/turkjsurg.2020.4696
   PubMed Web of Science ®Google Scholar
• Dong SY, Zeng RC, Jin LP, et al. BRAF(V600E) mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: different histological subtypes and preoperative lymph node status should be taken into account. Oncol Lett. 2017;14(4):4122–4134. doi:10.3892/ol.2017.6694
   PubMed Web of Science ®Google Scholar
• Özçelik S, Bircan R, Sarıkaya Ş, et al. BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure. Endokrynol Pol. 2019;70(5):401–408. doi:10.5603/EP.a2019.0025
   PubMed Web of Science ®Google Scholar
• Pessôa-Pereira D, Medeiros M, Lima VMS, et al. Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Arch Endocrinol Metab. 2019;63(2):97–106. doi:10.20945/2359-3997000000120
   PubMed Web of Science ®Google Scholar
• Park AY, Son EJ, Kim JA, et al. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. PLoS One. 2014;9(10):e110868. doi:10.1371/journal.pone.0110868
   PubMed Web of Science ®Google Scholar
• Ye Z, Xia X, Xu P, et al. The prognostic implication of the BRAF V600E mutation in papillary thyroid cancer in a Chinese population. Int J Endocrinol. 2022;2022:6562149. doi:10.1155/2022/6562149
   PubMed Web of Science ®Google Scholar
• Tao Y, Wang F, Shen X, et al. BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer. J Clin Endocrinol Metab. 2021;106(11):3228–3238. doi:10.1210/clinem/dgab286
   PubMed Web of Science ®Google Scholar
• Zheng X, Peng C, Gao M, et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1587 patients. Cancer Biol Med. 2019;16(1):121–130. doi:10.20892/j.issn.2095-3941.2018.0125
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhao Y, Chen K, et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma. J Endocrinol Invest. 2019;42(2):227–236. doi:10.1007/s40618-018-0908-y
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee YM, Sung TY, et al. Is male gender a prognostic factor for papillary thyroid microcarcinoma? Ann Surg Oncol. 2017;24(7):1958–1964. doi:10.1245/s10434-017-5788-4
   PubMed Web of Science ®Google Scholar
• Zhou C, Li J, Wang Y, Xue S, Zhang Y. Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma. Oncol Lett. 2019;17(1):183–194. doi:10.3892/ol.2018.9572
   PubMed Web of Science ®Google Scholar
• Chen BD, Zhang Z, Wang KK, et al. A multivariable model of BRAF(V600E) and ultrasonographic features for predicting the risk of central lymph node metastasis in cN0 papillary thyroid microcarcinoma. Cancer Manag Res. 2019;11:7211–7217. doi:10.2147/CMAR.S199921
   PubMed Web of Science ®Google Scholar
• Jin WX, Ye DR, Sun YH, et al. Prediction of central lymph node metastasis in papillary thyroid microcarcinoma according to clinicopathologic factors and thyroid nodule sonographic features: a case-control study. Cancer Manag Res. 2018;10:3237–3243. doi:10.2147/CMAR.S169741
   PubMed Web of Science ®Google Scholar
• Sun Y, Shi C, Shi T, Yu J, Li Z. Correlation between the BRAF(v600E) gene mutation and factors influencing the prognosis of papillary thyroid microcarcinoma. Int J Clin Exp Med. 2015;8(12):22525–22528. PMID: 26885238.
   PubMed Web of Science ®Google Scholar
• Zhou SL, Guo YP, Zhang L, et al. Predicting factors of central lymph node metastasis and BRAF(V600E) mutation in Chinese population with papillary thyroid carcinoma. World J Surg Oncol. 2021;19(1):211. doi:10.1186/s12957-021-02326-y
   PubMed Web of Science ®Google Scholar
• Issa PP, Omar M, Buti Y, et al. Hashimoto’s thyroiditis minimizes lymph node metastasis in BRAF mutant papillary thyroid carcinomas. Biomedicines. 2022;10(8):2051. doi:10.3390/biomedicines10082051
   PubMed Web of Science ®Google Scholar
• Ren H, Shen Y, Hu D, et al. Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res. 2018;10:1005–1013. doi:10.2147/CMAR.S159583
   PubMed Web of Science ®Google Scholar
• Jeon MJ, Chun SM, Lee JY, et al. Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis. Endocrine. 2019;64(1):130–138. doi:10.1007/s12020-019-01842-y
   PubMed Web of Science ®Google Scholar
• Dong Y, Wang D, Luo Y, et al. Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma. Oncol Lett. 2021;21(3):188. doi:10.3892/ol.2021.12449
   PubMed Web of Science ®Google Scholar
• Kim K, Zheng X, Kim JK, et al. The contributing factors for lateral neck lymph node metastasis in papillary thyroid microcarcinoma (PTMC). Endocrine. 2020;69(1):149–156. doi:10.1007/s12020-020-02251-2
   PubMed Web of Science ®Google Scholar
• Ji W, Xie H, Wei B, et al. Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma. Int J Clin Exp Pathol. 2019;12(9):3492–3499. PMID: 31934195.
   PubMed Web of Science ®Google Scholar
• Yu X, Song X, Sun W, Zhao S, Zhao J, Wang YG. Independent risk factors predicting central lymph node metastasis in papillary thyroid microcarcinoma. Horm Metab Res. 2017;49(3):201–207. doi:10.1055/s-0043-101917
   PubMed Web of Science ®Google Scholar
• Cupisti K, Lehwald N, Anlauf M, et al. Encapsulation status of papillary thyroid microcarcinomas is associated with the risk of lymph node metastases and tumor multifocality. Horm Metab Res. 2014;46(2):138–144. doi:10.1055/s-0033-1361158
   PubMed Web of Science ®Google Scholar
• Liu W, Wang S, Xia X. Risk factor analysis for central lymph node metastasis in papillary thyroid microcarcinoma. Int J Gen Med. 2021;14:9923–9929. doi:10.2147/IJGM.S346143
   PubMed Web of Science ®Google Scholar
• Yin Y, Xu X, Shen L, Zhao W, Diao H, Li C. Influencing factors and cumulative risk analysis of cervical lymph node metastasis of papillary thyroid microcarcinoma. Front Oncol. 2021;11:644645. doi:10.3389/fonc.2021.644645
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen C, Chen Z, et al. Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. Clin Endocrinol. 2014;81(2):282–288. doi:10.1111/cen.12417
   PubMed Web of Science ®Google Scholar
• Ş A, Yazgan Aksoy D, Akın S, Kılıç M, Yetişir F, Bayraktar M. Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma. Turk J Med Sci. 2017;47(6):1723–1727. doi:10.3906/sag-1702-99
   PubMed Web of Science ®Google Scholar
• Shi Y, Yang Z, Heng Y. Clinicopathological findings associated with cervical lymph node metastasis in papillary thyroid microcarcinoma: a retrospective study in China. Cancer Control. 2022;29:10732748221084926. doi:10.1177/10732748221084926
   Web of Science ®Google Scholar
• Zhao W, Chen S, Hou X, Liao Q, Chen G. Predictive factors of lateral lymph node metastasis in papillary thyroid microcarcinoma. Pathol Oncol Res. 2019;25(3):1245–1251. doi:10.1007/s12253-018-0511-8
   PubMed Web of Science ®Google Scholar
• Medas F, Canu GL, Cappellacci F, et al. Predictive factors of lymph node metastasis in patients with papillary microcarcinoma of the thyroid: retrospective analysis on 293 cases. Front Endocrinol. 2020;11:551. doi:10.3389/fendo.2020.00551
   PubMed Web of Science ®Google Scholar
• Parvathareddy SK, Siraj AK, Annaiyappanaidu P, Siraj N. Risk factors for cervical lymph node metastasis in middle eastern papillary thyroid microcarcinoma. J Clin Med. 2022;11(15):4613. doi:10.3390/jcm11154613
   PubMed Web of Science ®Google Scholar
• Wang Y, Nie F, Wang G, Liu T, Dong T, Sun Y. Value of combining clinical factors, conventional ultrasound, and contrast-enhanced ultrasound features in preoperative prediction of central lymph node metastases of different sized papillary thyroid carcinomas. Cancer Manag Res. 2021;13:3403–3415. doi:10.2147/CMAR.S299157
   PubMed Web of Science ®Google Scholar
• Gu JH, Zhao YN, Xie RL, et al. Analysis of risk factors for cervical lymph node metastasis of papillary thyroid microcarcinoma: a study of 268 patients. BMC Endocr Disord. 2019;19(1):124. doi:10.1186/s12902-019-0450-8
   PubMed Web of Science ®Google Scholar
• Zou Q, Ma S, Zhou X. Association of sonographic features and clinicopathologic factors of papillary thyroid microcarcinoma for prevalence of lymph node metastasis: a retrospective analysis. Arch Endocrinol Metab. 2021;64(6):803–809. doi:10.20945/2359-3997000000297
   PubMed Web of Science ®Google Scholar
• Gao Y, Wang Y, Guo R. NKD2 is correlated with the occurrence, progression and prognosis of thyroid carcinoma. Eur J Med Res. 2022;27(1):235. doi:10.1186/s40001-022-00853-2
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Z, Yan Z, Ma S. PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma. Adv Clin Exp Med. 2020;29(7):785–792. doi:10.17219/acem/121518
   PubMed Web of Science ®Google Scholar
• Munari E, Mariotti FR. PD-1/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects. Int J Mol Sci. 2021;22(10):5123. doi:10.3390/ijms22105123
   PubMed Web of Science ®Google Scholar
• Girolami I, Pantanowitz L, Mete O, et al. Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma. Endocr Pathol. 2020;31(3):291–300. doi:10.1007/s12022-020-09630-5
   PubMed Web of Science ®Google Scholar
• Marletta S, Fusco N. Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems. J Pers Med. 2022;12(7):1073. doi:10.3390/jpm12071073
   PubMed Web of Science ®Google Scholar
• Xu Y, Lu J, Lou N, et al. Long noncoding RNA GAS5 inhibits proliferation and metastasis in papillary thyroid carcinoma through the IFN/STAT1 signaling pathway. Pathol Res Pract. 2022;233:153856. doi:10.1016/j.prp.2022.153856
   PubMed Web of Science ®Google Scholar
• Perera D, Ghossein R, Camacho N, et al. Genomic and transcriptomic characterization of papillary microcarcinomas with lateral neck lymph node metastases. J Clin Endocrinol Metab. 2019;104(10):4889–4899. doi:10.1210/jc.2019-00431
   PubMed Web of Science ®Google Scholar